| Patient | Sir John Franklin |
|---|---|
| Date of birth | 1786-04-16 |
| Identifiers | MRN HR-EX005-SYN-TD; SSN (made up) 000-05-3328 |
| Document date | 1845-05-05 |
| Author | Cordelia Ashby-Nwankwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Pre-departure review two weeks before sailing. [S]
Sir John sails in two weeks. His home readings this week average 126/78 on amlodipine 5 mg, with no side effects. He has lost 3.9 kg since intake by his own plan and counts his weight goal as met. He is sleeping well and is busy and cheerful; he knows the polar winters will be long and dark and has planned a routine of work, lessons and exercise for the officers and men. He has his clothing, a home blood pressure monitor with a spare cuff, and copies of his medical plan for the ship's surgeons. He has had every planned vaccine except the second zoster dose, due today. [S]
| Element | Detail |
|---|---|
| Home readings | Seven-day average 126/78 mmHg |
| Weight | 86.9 kg, from 90.8 at intake |
| Mood | PHQ-9 2, item 9 scored 0; GAD-7 3 |
| Vitamin D | 34 ng/mL on vitamin D3 |
| Kidney function | Creatinine 0.96 mg/dL, eGFR 90; potassium 4.3 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; sleeping seven hours |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Ears, nose, mouth, and throat | Positive | Trouble hearing in noisy rooms, unchanged |
| Psychiatric | Negative | Mood good; no worry he cannot manage |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 1845-01-27 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters | One tablet by mouth daily | Oral route | 1845-01-27 | active | S |
| Vitamin C (ascorbic acid) 250 mg oral tablet once daily for the whole expedition, stored sealed and away from heat and light, in addition to food sources | One tablet by mouth daily from departure | Oral route | 1845-05-05 | active | S |
| Oseltamivir 75 mg oral capsule twice daily for five days | One capsule by mouth twice a day for five days | Oral route | 1845-02-10 to 1845-02-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1845-05-05 | Body height | 170 | cm | S |
| 1845-05-05 | Body weight | 86.9 | kg | S |
| 1845-05-05 | Body mass index (BMI) [Ratio] | 30.1 | kg/m2 | S |
| 1845-05-05 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1845-05-05 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1845-05-05 | Heart rate | 68 | /min | S |
| 1845-05-05 | Respiratory rate | 14 | /min | S |
| 1845-05-05 | Body temperature | 36.6 | Cel | S |
| 1845-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1845-05-05 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-146 mmol/L | Normal | S |
| 1845-05-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 1845-05-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1845-05-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1840)/1.73 sq M | 90 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1845-05-05 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Normal | S |
| 1845-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1845-05-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S |
Vital signs recorded on 1845-05-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 68; weight 86.9 kg, BMI 30.1; waist 101 cm |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Skin | Hands, feet and face intact; no old cold injury |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| High blood pressure found at the pre-expedition medical (152/94 mmHg, average of two readings), without a prior diagnosis; home readings for one week ordered to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding at a pre-expedition fitness assessment, anchored to the documented doubts about his fitness; superseded when home readings confirmed hypertension. |
| Essential hypertension, stage 2 by home readings (one-week average 144/90 mmHg), without target-organ damage; synthetic | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home monitoring at the consultation; no blood pressure from his lifetime is recorded. |
| Obesity, class 1 (BMI 31.4 at intake), with a waist of 106 cm; he sets his own goals for activity and food | active | confirmed | E66.811 | S — Synthetic modern finding anchored to the documented description of his build as portly; no weight from his lifetime is recorded. |
| Medical preparation for a multi-year Arctic expedition beyond the reach of hospital care: fitness, cold injury, nutrition and food safety, vaccinations, dental care, mental health in isolation, a medical kit and an evacuation plan | active | confirmed | Z71.84 | S — Synthetic travel-health problem anchored to the documented expedition. |
| Bilateral high-frequency sensorineural hearing loss from noise, mild; trouble hearing in noisy rooms | active | confirmed | H83.3X3 | S — Synthetic modern coding of the documented mild hearing loss from naval gunfire; the audiogram is synthetic. |
| Vitamin D insufficiency in midwinter (25-hydroxyvitamin D 22 ng/mL), with years of polar darkness ahead | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
| Influenza A, confirmed by rapid molecular test, with fever, cough and aches, without pneumonia; treated with oseltamivir; recovered with a lingering cough | resolved | confirmed | J10.1 | S — Synthetic modern illness anchored to the documented severe influenza of the winter before the expedition; the test, course and treatment are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, large cuff, average of two readings) | Every visit | Completed today | 126/76 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and two to four weeks after each treatment change, then weekly | Completed today | Average 126/78 mmHg; weekly readings on board |
| Examination | Weight, BMI and waist | Every visit | Completed today | 86.9 kg, BMI 30.1, waist 101 cm; 4.3 percent lost |
| Examination | Cardiac auscultation | Every visit | Completed today | No murmur or gallop |
| Laboratory | Basic metabolic panel, potassium and eGFR | Yearly (every six months only on a diuretic or renin-angiotensin blocker) | Completed today | Sodium 139, potassium 4.3, creatinine 0.96 mg/dL, eGFR 90: a baseline before departure |
| Laboratory | 25-hydroxyvitamin D | Three months after starting vitamin D3 | Completed today | 34 ng/mL, from 22 |
| Laboratory | Lipid panel and HbA1c or fasting glucose | Yearly | Up to date | Due on his return |
| Survey | PHQ-9 depression screen and GAD-7 | Yearly, and before isolation | Completed today | PHQ-9 2 with item 9 scored 0; GAD-7 3 |
| Medication safety | Amlodipine safety: ankle swelling, dizziness, flushing | At each visit | Completed today | No side effects; three-year supply dispensed with written dose rules |
| Self-management | Nutrition and food safety for the expedition (vitamin C and D, rations, cans, lead, botulism) | Before departure | Completed today | Vitamin C 250 mg daily from today; vitamin D3 continued; can inspection rules in writing |
| Self-management | Cold injury and hypothermia prevention | Before departure | Up to date | Training done; clothing fitted |
| Self-management | Medical kit, written plan for the ship's surgeons, and evacuation plan | Before departure | Completed today | Kit list, written plan for the surgeons, and his written wishes for serious illness on board |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, second of two doses [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and hyperlipidemia monographs (2026); Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (2024); Wilderness Medical Society Clinical Practice Guidelines for the Out-of-Hospital Evaluation and Treatment of Accidental Hypothermia: 2019 Update (2019); Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 (2021); Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Full review on his return, with lipids, HbA1c, kidney function, urine albumin and blood lead. [S]